Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban prophylaxis for venous thromboembolism in myeloma patients treated with IMiDs
2013-003190-99Phase 3Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of apixaban in multiple myeloma (MM), sponsored by CHU Grenoble Alpes. Primary endpoint: Total venous thromboembolism and VTE-related death. Started Sep 2015; status: completed.
02
Drugs
apixaban
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-003190-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003190-99.